Creative Medical Technology Holdings completed enrollment and treatment across its FDA-cleared ADAPT trial of CELZ-201 (Olastrocel) for chronic lower back pain.
Results were already presented in prior interim readouts, showing encouraging early signs of pain and function improvement with a favorable safety profile.
The FDA-cleared opioid-use expansion cohort also finished dosing, supporting evaluation in a more commercially relevant patient population.
Spending tied to recruitment and treatment is expected to ease as the study shifts to follow-up, data maturation, RMAT evaluation, and Phase 3 planning.
CELZ•
